28/06/2007 13:00:00

Quantum Genomics Corp Partners with Inserm and CNRS in Hypertension Drug Development

Quantum Genomics Corp. (QGC), a global biotech company developing

new drugs for metabolic and cardiovascular diseases, announced

partnership agreements with Inserm, the French national institute for

health and medical research and the CNRS, France´s national center for

scientific research, and University Paris Descartes. The agreement

brings together some of the best scientific skills in the field of

cardiovascular diseases from two leading life science research

organizations and a premier university along with biotechnology

business experience from QGC, to successfully co-develop innovative

drugs.

The agreement covers a lead molecule derived from discoveries by

teams led respectively by Dr Catherine Llorens-Cortes, director of

Inserm Unit 691, based in the College de France and by Prof. Bernard

P. Roques at Inserm Unit 640, itself based in the University of Paris

Descartes.

The purpose of the agreement is to co-develop innovative drugs for

hypertension and related cardiovascular diseases. Under the terms of

the contract, QGC acquires rights to exploit three patents and

associated know-how. Inserm and CNRS will work on the physiopathology,

chemistry and the understanding of the compound´s mechanism of action

whereas QGC will handle preclinical and clinical development and

regulatory aspects.

The first lead molecule to be developed will be QGC001, a new

chemical entity. This compound acts according to a new biological

mechanism with a huge potential to facilitate control of blood

pressure in patients who are resistant to currently available

anti-hypertension drugs. QGC expects to start the first clinical trial

in humans in 2008.

"We are delighted to be partnering with Inserm and CNRS, two of

the world´s leading healthcare research organizations," said Lionel

Segard, Chairman and CEO of QGC. "This project lets QGC demonstrate

its ability to develop new drugs in compliance with international

regulatory guidelines. It also significantly reinforces QGC´s

potential in R&D in the field of cardiovascular diseases."

"This partnership with QGC gives us an excellent opportunity to

accelerate the pre-clinical and clinical development of a project

based on work carried out in our labs in close cooperation with

Bernard Roques´ team," said Catherine Llorens Cortes, director of

Inserm Unit 691.

Cardiovascular diseases are one of the main causes of death in

humans. Hypertension in particular is one of the major determining

factors in premature death. The risk of myocardial infarction, stroke,

kidney failure, heart failure or other complications doubles with

every 20/10mmHg rise in blood pressure. At least 30% of people have

hypertension. Hundreds of millions of people worldwide suffer from

hypertension complications despite medical advice on food and health

habits and the existence of several treatments. The market for

hypertensive drugs is expected to double between 2005 and 2010.

About Quantum Genomics Corp.

QGC is a biotechnology company seeking to develop new therapies in

areas where an unmet medical need exists. QGC focus is on

metabolism-related diseases and cardiovascular pathologies. It will

co-develop some products with academic teams and will set up strategic

alliances and commercial partnerships to cover all areas of research

in life sciences.

The company is headquartered in Jersey City, New Jersey, USA. It

has a European office in France under the leadership of Lionel Segard.

For more information go to www.Quantum-Genomics.com

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
15 Sep
 
  Jeg forstår ikke, at EI tillader en skribent som Baronen84, at forpeste hele forummet med løgn, hå..
46
15 Sep
BAVA
FUCK, hvor er disse to usympatiske individer belastende. Ved godt jeg ikke burde starte denne tråd, ..
36
15 Sep
BAVA
Jeg tillader mig at starter en ny tråd med det som jeg har skrevet tidligere til den hån Baron84 har..
33
15 Sep
BAVA
Har vel tabt omkring 225K men det er ikke det værste. Det værste er at der så stadig ikke er en orde..
29
18 Sep
FING-B
Goodwrench, sikke en omgang vrøvl.   Det er ikke kun hyklerisk, men også dybt patetisk, når du komme..
27
16 Sep
BAVA
Personligt vil jeg jo sige, at nu er der det gode til BN tilbage, så hvis man fik en over snuden så ..
26
13 Sep
GEN
Enig BlackThursday - der er lang vej endnu, men den prækliniske pakke vokser, hvilket bestemt gør at..
23
16 Sep
BAVA
Først - surt show - been there, done that - så kender følelsen! Har set mange som har skrevet - at ..
22
19 Sep
PNDORA
Her er min model ;)      
20
17 Sep
 
er højt i kurs her  .   Det er synd, at voksne mennesker ikke har mere pli, så snart de er anonyme .
18

G4S plc DK : Notification of Major Shareholding

19/09/2017 13:55:10
19 September 2017 G4S PLC NOTIFICATION OF MAJOR SHAREHOLDING The company received notification on 18 September by Harris Associates L.P., that, following an acquisition of voting rights on 14 September 2017, it now holds 5.11% of the company's total voting rights. Celine Barroche Company Secretary For further enquiries, please contact: Helen Parris - Director of In..

Dimensional Fund Advisors Ltd. : Form 8.3 - John Wood Group Plc - Ordinary shares

19/09/2017 10:16:48
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser:   Dimensional Fund Advisors Ltd. ("Dimensional"), in its capacity ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Solvay enters into a binding agreement to sell its Polyamides business to BASF, a landmark in Solvay's transformation
2
Solvay restates financial information following discontinuation of polyamide and updates 2017 guidance
3
Autostrade BNP Paribas Primary New Issues : NO STAB Notice
4
TRANSDIGM GROUP SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against TransDigm Group Incorporated - (TDG)
5
H1 2017 WISeKey Revenue Increased by over 1,500% to $21.2 Million; Reduced Losses by 80% and is on the Path to Profitability

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
20 September 2017 03:09:53
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170915.2 - EUROWEB3 - 2017-09-20 04:09:53 - 2017-09-20 03:09:53 - 1000 - Website: OKAY